Premium
Variability of biomarkers in patients with chronic heart failure and healthy controls
Author(s) -
Meijers Wouter C.,
van der Velde A. Rogier,
Muller Kobold Anneke C.,
DijckBrouwer Janneke,
Wu Alan H.,
Jaffe Allan,
de Boer Rudolf A.
Publication year - 2017
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.669
Subject(s) - medicine , biomarker , heart failure , galectin 3 , cardiology , creatinine , gdf15 , natriuretic peptide , gastroenterology , endocrinology , biology , biochemistry
Aims Biomarkers can be used for diagnosis, risk stratification, or management of patients with heart failure ( HF ). Knowledge about the biological variation is needed for proper interpretation of serial measurements. Therefore, we aimed to determine and compare the biological variation of a large panel of biomarkers in healthy subjects and in patients with chronic HF . Methods and results The biological variability of established biomarkers [ NT‐proBNP and high‐sensitivity troponin T ( hsTnT )], novel biomarkers [galectin‐3, suppression of tumorigenicity 2 ( ST2 ), and growth differentiation factor 15 ( GDF ‐15)], and renal/neurohormonal biomarkers (aldosterone, phosphate, parathyroid hormone, plasma renin concentration, and creatinine) was determined in 28 healthy subjects and 83 HF patients, over a period of 4 months and 6 weeks, respectively. The analytical ( CV a ), intraindividual ( CV i ), and interindividual ( CV g ) variations were calculated, as well as the reference change value ( RCV ), which reflects the percentage of change that may indicate a ‘relevant’ change. All crude biomarker levels were significantly increased or decreased in HF patients compared with controls (all P < 0.01). Variation indices were comparable in healthy individuals and HF patients. CV i was not influenced by the individual levels of the biomarker itself. NT‐proBNP and GDF ‐15 had relatively high CV i (21.8% and 16.6%) and RCV (61.7% and 64.3%), whereas ST2 ( CV i , 15.0; RCV , 42.9%), hsTnT ( CV i , 11.1; RCV , 31.4%), and galectin‐3 ( CV i , 8.1; RCV , 25.0%) had lower indices of variation. Conclusion Biological variation indices are comparable between healthy subjects and HF patients for a broad spectrum of biomarkers. NT‐proBNP and GDF ‐15 have substantial variation, with lower variation for ST2 , hsTnT , and galectin‐3. These data are instrumental in proper interpretation of biomarker levels in HF patients.